[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574289":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":22,"locations":28,"responsibleParty":36,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":7,"studyType":53,"phases":7,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":63,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Hospital de Clinicas José de San Martín","OTHER",null,[9,13,16,19],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Fecal elastase","\\*\\*Stool Samples\\*\\* To investigate exocrine pancreatic insufficiency (EPI), a stool sample will be requested from all patients for fecal elastase (Fel-1) analysis. Participants will be instructed to collect their stool sample in a sterile, disposable plastic container and submit it to the Gastroenterology Chemistry Laboratory (Litwin Laboratory) for processing and analysis. Based on previously published reports, samples will be stored refrigerated at 4-8 °C for no more than 48 hours. The concentrations of Fel-1 in all samples will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (ScheBo-Pancreatic Elastase 1™, Giessen, Germany), and fecal elastase will be extracted and analyzed according to the manufacturer's instructions.",{"type":10,"name":14,"description":15,"armGroupLabels":7,"otherNames":7},"Ecoendoscopy","\\*\\*Diagnosis of Pancreatic Steatosis\\*\\* The diagnosis of pancreatic steatosis will be performed using endoscopic ultrasound. A Pentax EG-3870UTK endoscope will be used in conjunction with Hitachi Avius ultrasound equipment. The procedure is performed under anesthesia using propofol.",{"type":10,"name":17,"description":18,"armGroupLabels":7,"otherNames":7},"Fibroscan","\\*\\*Fibroscan Procedure:\\*\\* This is a new technique based on the evaluation of liver elasticity or stiffness that allows for the measurement of liver hardness and quantification of liver fibrosis in a simple and completely painless manner using ultrasound. The results are obtained immediately and can be safely repeated periodically.",{"type":10,"name":20,"description":21,"armGroupLabels":7,"otherNames":7},"Serum cytokines","Peripheral blood will be drawn from all participants in the Gastroenterology Division of the Hospital de Clínicas. Samples will be collected in EDTA tubes, centrifuged, and the serum will be frozen at -80 °C until processing. Serum cytokine levels will be measured using a commercial kit (Bio-Plex Pro human cytokine, Bio-Rad Lab., Inc.), which includes a panel of 27 cytokines: FGF basic, Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, MIP-1α, IL-12 (p70), MIP-1β, IL-13, PDGF-BB, IL-15, RANTES, IL-17, TNF-α, IP-10, VEGF, MCP-1 (MCAF).",[23],{"name":24,"role":25,"phone":26,"phoneExt":7,"email":27},"MARIA M PISKORZ, MD","CONTACT","+5491133192885","neurogastrohc@gmail.com",[29],{"facility":30,"status":7,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":7,"geoPoint":7,"contacts":7},"Hospital de Clinicas Jose de San Martin","Ciudad Autonoma de Buenos Aires","Buenos Aires","1119","Argentina","AR",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Maria Marta Piskorz","Principal Investigator","100574289","fatty-liver-and-pancreatic-steatosis-100574289",false,"NCT06757348","Fatty Liver and Pancreatic Steatosis","Association Between Fatty Liver and Pancreatic Steatosis in Patients With Metabolic Syndrome","Inclusion Criteria:\n\n* Patients over 18 years old with a diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).\n\nExclusion Criteria:\n\n* \\- Alcohol consumption \\>20 g\u002Fday in women, \\>30 g\u002Fday in men\n* Chronic hepatitis B or C infection\n* Autoimmune liver diseases: autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis\n* Hereditary hemochromatosis\n* Wilson's disease\n* Alpha-1 antitrypsin deficiency\n* Celiac disease\n* Uncontrolled thyroid disease\n* Active or chronic infectious disease\n* Active cancer or ongoing treatment\n* Chronic renal insufficiency\n* Pregnancy\u002Flactation\n* Insufficient data\n* Patients who do not complete follow-up","ALL","18 Years","65 Years",{"count":51,"type":52},61,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients.\n\nParticipants with fatty liver and metabolic syndrome will undergo fecal elastase measurement and endoscopic ultrasound (EUS).",[56,57,58],"Exocrine Pancreatic Insufficiency","Fatty Liver, Nonalcoholic","Pancreatic Steatosis",[60,61,62],"Fatty liver","Pancreatic steatosis","Metabolic syndrome","NOT_YET_RECRUITING","2025-08-05",{"date":66,"type":67},"2025-08-06","ACTUAL",{"date":69,"type":52},"2025-09-01",{"date":71,"type":52},"2026-03-01",{"name":38,"class":6},1]